Which opioid formulation is NOT considered abuse deterring?

The formulations recognized as abuse-deterrent are designed to deter the manipulation of opioids for misuse and to minimize the potential for addiction. Many extended-release formulations of opioids, such as ER Hydrocodone and Oxydone, typically incorporate technology aimed at reducing the likelihood of abuse, such as physical and chemical barriers to prevent crushing, snorting, or injecting.

Extended-release Morphine is also developed with similar strategies to limit misuse. Tapentadol has some abuse-deterrent features as well, specifically aimed at making it less desirable for diversion.

In contrast, immediate-release formulations, like Oxycodone IR, do not contain the same technologies that make abuse deterrence feasible. These compounds can often be more readily manipulated for unintended use, therefore not falling under the category of abuse-deterrent formulations.

This distinction underscores why the identified formulation, in this case, is not considered abuse-deterrent compared to the others listed.